Free Trial
→ The chokepoint supplier behind SpaceX's $1.75 trillion empire (From Behind the Markets) (Ad)tc pixel
NASDAQ:MDWD

MediWound Q1 2026 Earnings Report

MediWound logo
$16.66 -0.61 (-3.51%)
As of 12:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

MediWound EPS Results

Actual EPS
N/A
Consensus EPS
-$0.65
Beat/Miss
N/A
One Year Ago EPS
N/A

MediWound Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.37 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

MediWound Announcement Details

Quarter
Q1 2026
Date
5/20/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

MediWound Earnings Headlines

MediWound to Report First Quarter 2026 Financial Results
May 7 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3289907/30505/en/mediwound-to-report-first-quarter-2026-financial-results.html
MediWound Shareholders Back Board, Auditor and CEO Bonus at 2026 Annual Meeting
May 6 at 4:51 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/mediwound-shareholders-back-board-auditor-and-ceo-bonus-at-2026-annual-meeting?utm_source=marketbeat.com&utm_medium=referral
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
May 8 at 1:00 AM  |  Brownstone Research (Ad)
Analysts Offer Insights on Healthcare Companies: Simulations Plus (SLP) and Mediwound (MDWD)
April 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SLP/pressreleases/1178512/analysts-offer-insights-on-healthcare-companies-simulations-plus-slp-and-mediwound-mdwd/
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
April 13, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/newly-published-u-s-expert-consensus-aligns-with-mediwound-s-strategy-for-chronic-wound-debridement-1036015144
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
April 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/13/3272390/30505/en/newly-published-u-s-expert-consensus-aligns-with-mediwound-s-strategy-for-chronic-wound-debridement.html
See More MediWound Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediWound? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediWound and other key companies, straight to your email.

About MediWound

MediWound (NASDAQ:MDWD) (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue. NexoBrid has received regulatory approval in the European Union and by the U.S. Food and Drug Administration for use in adults with severe thermal burns. MediWound is also advancing EscharEx™, a topical therapy aimed at debriding chronic and hard-to-heal wounds, currently undergoing pivotal clinical trials to expand its therapeutic portfolio.

MediWound’s commercial reach spans North America, Europe and other international markets through a network of strategic distribution partners. In the United States, the company supports its sales efforts with a dedicated subsidiary and field-based clinical specialists, while in Europe it works with established distributors to ensure product availability and regulatory compliance. The company continues to explore additional indications and territories to broaden access to its enzymatic treatments.

Leadership at MediWound is spearheaded by Chief Executive Officer Dan Rosenwasser, who has guided the company’s strategic expansion and commercialization initiatives. Under his direction, MediWound has strengthened its manufacturing capabilities and fortified its clinical pipeline. The management team’s combined expertise in biotechnology, regulatory affairs and commercial operations underpins the company’s mission to deliver advanced wound care solutions to patients worldwide.

View MediWound Profile
Earnings Tools